Having trouble accessing articles? Reset your cache.

Biogen, Novartis carve out space for their SMA therapies

Biogen and Novartis each posted consensus-beating quarters for their respective spinal muscular atrophy therapies, with ex-U.S. sales and a wider indication allowing Spinraza to stay in the game as gene therapy Zolgensma is poised to encroach on those markets.

Zolgensma onasemnogene abeparvovec-xioi from Novartis AG (NYSE:NVS; SIX:NOVN) brought in revenues

Read the full 493 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE